Baudax Bio Inc.
| NASDAQ: BXRX | Healthcare / Biotechnology / USA |
| 1.55 | -0.0100 | -0.64% | Vol 92.42K | 1Y Perf -22.00% |
| Mar 24th, 2023 15:59 DELAYED |
| BID | 1.55 | ASK | 1.59 | ||
| Open | 1.52 | Previous Close | 1.56 | ||
| Pre-Market | - | After-Market | 1.55 | ||
| - - | - -% |
| Target Price | 80.00 | Analyst Rating | Hold 3.00 | |
| Potential % | 5.06K | Finscreener Ranking | ★★ 45.19 | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | ★+ 43.24 | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | ★+ 43.28 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | ★★★+ 46.94 | |
| Price Range Ratio 52W % | 0.33 | Earnings Rating | — | |
| Market Cap | 4.01M | Earnings Date | 3rd May 2023 | |
| Alpha | -0.12 | Standard Deviation | 0.27 | |
| Beta | 1.68 |
Today's Price Range 1.511.68 | 52W Range 1.2591.20 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -13.41% | ||
| 1 Month | -30.80% | ||
| 3 Months | -32.61% | ||
| 6 Months | 496.15% | ||
| 1 Year | -22.00% | ||
| 3 Years | -33.76% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 87.76 | |||
ROE last 12 Months | 111.92 | |||
ROA (5Y Avg) | -42.28 | |||
ROA last 12 Months | -57.04 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -134.53 | |||
Return on invested Capital Q | -47.90 | |||
Return on invested Capital Y | - | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.68 | ||||
| 5.28 | ||||
| - | ||||
| -0.10 | ||||
| -230.20 | ||||
| -0.07 | ||||
| -35.21 | ||||
| 4.11M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.30 | ||||
| 0.50 | ||||
| 0.55 | ||||
| 2.06 | ||||
| -33.70 | ||||
| Leverage Ratio | -19.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -105.50 | ||||
| -442.90 | ||||
| -240.80 | ||||
| - | ||||
| -30.55 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 959.00K | ||||
| 0.62 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 487.81 | ||||
| 16.00 | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2022 | - | -12.33 | - |
| Q03 2022 | -21.20 | -98.80 | -366.04 |
| Q02 2022 | -50.80 | -42.00 | 17.32 |
| Q01 2022 | -74.00 | -126.80 | -71.35 |
| Q04 2021 | - | 401.60 | - |
| Q03 2021 | -223.78 | -279.72 | -25.00 |
| Q02 2021 | -7.69 | -7.34 | 4.55 |
| Q01 2021 | -6.64 | -6.64 | 0.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 3rd May 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 92.42K |
| Shares Outstanding | 2.59K |
| Shares Float | 6.37M |
| Trades Count | 437 |
| Dollar Volume | 147.17K |
| Avg. Volume | 929.42K |
| Avg. Weekly Volume | 367.59K |
| Avg. Monthly Volume | 631.05K |
| Avg. Quarterly Volume | 1.79M |
Baudax Bio Inc. (NASDAQ: BXRX) stock closed at 1.55 per share at the end of the most recent trading day (a -0.64% change compared to the prior day closing price) with a volume of 92.42K shares and market capitalization of 4.01M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 57 people. Baudax Bio Inc. CEO is Gerri A. Henwood.
The one-year performance of Baudax Bio Inc. stock is -22%, while year-to-date (YTD) performance is -51.26%. BXRX stock has a five-year performance of %. Its 52-week range is between 1.25 and 91.2, which gives BXRX stock a 52-week price range ratio of 0.33%
Baudax Bio Inc. currently has a PE ratio of 0.00, a price-to-book (PB) ratio of 0.68, a price-to-sale (PS) ratio of 5.28, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -57.04%, a ROC of -134.53% and a ROE of 111.92%. The company’s profit margin is -30.55%, its EBITDA margin is -240.80%, and its revenue ttm is $959.00 Thousand , which makes it $0.62 revenue per share.
Of the last four earnings reports from Baudax Bio Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Baudax Bio Inc.’s next earnings report date is 03rd May 2023.
The consensus rating of Wall Street analysts for Baudax Bio Inc. is Hold (3), with a target price of $80, which is +5 061.29% compared to the current price. The earnings rating for Baudax Bio Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Baudax Bio Inc. has a dividend yield of 487.80% with a dividend per share of $16.00 and a payout ratio of -%.
Baudax Bio Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 24.61, ATR14 : 0.25, CCI20 : -43.48, Chaikin Money Flow : 0.34, MACD : -0.26, Money Flow Index : 81.91, ROC : -10.40, RSI : 38.60, STOCH (14,3) : 33.34, STOCH RSI : 0.00, UO : 51.29, Williams %R : -66.66), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Baudax Bio Inc. in the last 12-months were:
Baudax Bio Inc.
Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings.
CEO: Gerri A. Henwood
Telephone: +1 484 395-2470
Address: 490 Lapp Road, Malvern 19355, PA, US
Number of employees: 57
